Precigen, Inc.
PGEN
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.88
Price+2.94%
$0.20
1Y
Price
Market Cap
$2.451b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+41.9%
EBITDA Margin+36.5%
Net Profit Margin-33.1%
Free Cash Flow Margin+41.9%
EBITDA Margin+36.5%
Net Profit Margin-33.1%
Free Cash Flow MarginRevenue
$85.717m
+785.1%
1y CAGR+298.3%
3y CAGR+204.5%
5y CAGREarnings
-$157.705m
+37.1%
1y CAGR-31.0%
3y CAGR-132.9%
5y CAGREPS
-$1.14
+19.2%
1y CAGR-67.1%
3y CAGR-49.7%
5y CAGRBook Value
$43.576m
$170.296m
Assets$126.720m
Liabilities$98.345m
DebtDebt to Assets
57.8%
-0.7x
Debt to EBITDAFree Cash Flow
-$115.826m
-28.9%
1y CAGR-19.4%
3y CAGR-14.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company